Nash Pharmaceuticals, a wholly-owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH, OTCQB: BTHCD, Forum), stated this week that it will be changing its name to Algernon Pharmaceuticals Inc. before market opens on February 19, 2019 and the Company’s ticker symbol will change from BTH to AGN on the Canadian Securities Exchange.
For more on the name change, click here.
The Company recently made newswith the announcement that its leadership will be presenting its pre-clinical data on its non-alcoholic steatohepatitis research program at the 2nd Global NASH Congress in London, U.K., February 25th & 26th, 2019.
FULL DISCLOSURE: Breathtec Biomedical Inc. is a client of Stockhouse Publishing.